Aim Vaccine Co. Ltd. may become the first company to gain regulatory clearance of a prophylactic iterative serum-free human rabies vaccine. Beijing-based Aim said it is preparing a regulatory submission of its independently developed rabies vaccine based on positive phase III results that showed good safety, immunogenicity and immune persistence.
Researchers from Diosynvax Ltd. presented data from a study that aimed to evaluate the efficacy of a pan-H5 vaccine designed using computational biology and being developed for protection against avian influenza.
Peptide-based vaccines deliver tumor-specific antigens to dendritic cells (DCs), triggering tumor-targeted T-cell responses. A peptide-peptide conjugate technology previously developed by researchers from Uppsala University and collaborators enhances this process by using multiple tetanus toxin-derived B-cell epitopes (MTTEs) to facilitate in vivo antigen delivery and DC activation.
Jay Bhattacharya will have his work cut out for him if he wins confirmation as the next director of the U.S. NIH. Besides getting NIH committees back on track to evaluate grant applications and calming the fears of researchers and other staff who have seen about 1,200 colleagues cut from their ranks in recent weeks, Bhattacharya will face the task of rebuilding public trust in the NIH itself.
As U.S. regulatory uncertainty swirls around the vaccine space and health care in general, Vaxcyte Inc. stands poised for a readout of phase II infant data by the end of this quarter with VAX-24, the 24-valent pneumococcal conjugate vaccine (PCV). The San Carlos, Calif.-based firm will offer top-line safety, tolerability, and immunogenicity data, to be followed by top-line data with the booster dose by the end of this year.
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has announced it will award US$2 million to Immunethep SA to develop a conjugated peptide-based vaccine to prevent infections from all invasive serotypes of Escherichia coli.
Io Biotech Aps has presented preclinical data regarding their Arg1-derived peptide cancer vaccine IO-112 as a potential immunotherapeutic that would allow controlling the tumor microenvironment.
With the U.S. FDA’s approval of Vimkunya, Bavarian Nordic A/S is now in the chikungunya virus infection mix along with Valneva SE’s Ixchiq. A single-dose, adjuvanted virus-like particle-based vaccine to protect against the chikungunya virus infection, Vimkunya is the first of its kind available in the U.S. for those age 12 and older.
A second pentavalent vaccine for preventing meningococcal disease has been approved by the U.S. FDA. GSL plc’s Penmenvy will now go up against Pfizer Inc.’s Penbraya, which had a two-year head start in the market.
RSS
